Michael Weintraub Sells 861 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub sold 861 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $25.26, for a total transaction of $21,748.86. Following the sale, the director now owns 242,827 shares of the company’s stock, valued at $6,133,810.02. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Michael Weintraub also recently made the following trade(s):

• On Friday, December 13th, Michael Weintraub sold 20,565 shares of Phreesia stock. The stock was sold at an average price of $25.04, for a total transaction of $514,947.60.
• On Monday, December 2nd, Michael Weintraub sold 15,152 shares of Phreesia stock. The stock was sold at an average price of $21.01, for a total value of $318,343.52.

Phreesia Stock Down 3.0 %

Shares of PHR stock opened at $24.87 on Wednesday. The company’s fifty day simple moving average is $20.60 and its two-hundred day simple moving average is $21.88. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16. The stock has a market cap of $1.45 billion, a P/E ratio of -16.92 and a beta of 0.98. The company has a quick ratio of 1.77, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. During the same period in the prior year, the company earned ($0.58) earnings per share. The firm’s revenue was up 16.6% on a year-over-year basis. Analysts predict that Phreesia, Inc. will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Phreesia

Large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its position in Phreesia by 8.4% in the second quarter. Bank of New York Mellon Corp now owns 214,430 shares of the company’s stock worth $4,546,000 after acquiring an additional 16,614 shares in the last quarter. Peregrine Capital Management LLC raised its holdings in Phreesia by 11.3% during the 2nd quarter. Peregrine Capital Management LLC now owns 354,607 shares of the company’s stock valued at $7,518,000 after buying an additional 36,047 shares during the period. nVerses Capital LLC lifted its position in Phreesia by 76.5% in the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after buying an additional 1,300 shares during the last quarter. Rhumbline Advisers boosted its stake in Phreesia by 1.0% during the second quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock worth $1,741,000 after buying an additional 853 shares during the period. Finally, Arcadia Investment Management Corp MI increased its position in Phreesia by 13.9% during the second quarter. Arcadia Investment Management Corp MI now owns 88,625 shares of the company’s stock valued at $1,879,000 after acquiring an additional 10,800 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

PHR has been the subject of a number of analyst reports. JPMorgan Chase & Co. upped their price target on Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday, September 9th. JMP Securities restated a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Truist Financial upped their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada restated a “sector perform” rating and set a $23.00 price objective on shares of Phreesia in a research report on Friday, September 27th. Finally, Robert W. Baird dropped their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.